These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 3130780)

  • 21. Antibody production to a meningococcal outer membrane protein cloned into liv Salmonella typhimurium aroA vaccine strain.
    Tarkka E; Muotiala A; Karvonen M; Saukkonen-Laitinen K; Sarvas M
    Microb Pathog; 1989 May; 6(5):327-35. PubMed ID: 2505011
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy.
    Milagres LG; Ramos SR; Sacchi CT; Melles CE; Vieira VS; Sato H; Brito GS; Moraes JC; Frasch CE
    Infect Immun; 1994 Oct; 62(10):4419-24. PubMed ID: 7927704
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune responses in mice to different noncovalent complexes of meningococcal B polysaccharide and outer membrane proteins.
    Lifely MR; Wang Z
    Infect Immun; 1988 Dec; 56(12):3221-7. PubMed ID: 3141286
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protection against group B Neisseria meningitidis disease: effect of serogroup B polysaccharide and polymyxin B on immunogenicity of serotype protein preparations.
    Peppler MS; Frasch CE
    Infect Immun; 1982 Jul; 37(1):264-70. PubMed ID: 6809628
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Appearance of new strains associated with group B meningococcal disease and their use for rapid vaccine development.
    Frasch CE; Mocca LF; Karpas AB
    Antonie Van Leeuwenhoek; 1987; 53(6):395-402. PubMed ID: 3130778
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A potential polyvalent Neisseria meningitidis vaccine based on a mixture of CaCl2 cell extracts from groups A, B and Y.
    Bisaillon JG; McSween G; Portelance V; Beaudet R; Morosoli R; Pouliot P; Micusan V
    Microbios; 1989; 60(244-245):193-208. PubMed ID: 2515422
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity studies with a genetically engineered hexavalent PorA and a wild-type meningococcal group B outer membrane vesicle vaccine in infant cynomolgus monkeys.
    Rouppe van der Voort E; Schuller M; Holst J; de Vries P; van der Ley P; van den Dobbelsteen G; Poolman J
    Vaccine; 2000 Jan; 18(14):1334-43. PubMed ID: 10618530
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outer membrane vesicle vaccines made from short-chain lipopolysaccharide mutants of serogroup B Neisseria meningitidis: effect of the carbohydrate chain length on the immune response.
    Andersen SR; Bjune G; Høiby EA; Michaelsen TE; Aase A; Rye U; Jantzen E
    Vaccine; 1997 Aug; 15(11):1225-34. PubMed ID: 9286048
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Humoral immune response to the class 3 outer membrane protein during the course of meningococcal disease.
    Guttormsen HK; Wetzler LM; Naess A
    Infect Immun; 1993 Nov; 61(11):4734-42. PubMed ID: 8406872
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protective efficacy of monoclonal antibodies to class 1 and class 3 outer membrane proteins of Neisseria meningitidis B:15:P1.16 in infant rat infection model: new prospects for vaccine development.
    Saukkonen K; Abdillahi H; Poolman JT; Leinonen M
    Microb Pathog; 1987 Oct; 3(4):261-7. PubMed ID: 3143885
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity of in vitro folded outer membrane protein PorA of Neisseria meningitidis.
    Jansen C; Kuipers B; van der Biezen J; de Cock H; van der Ley P; Tommassen J
    FEMS Immunol Med Microbiol; 2000 Mar; 27(3):227-33. PubMed ID: 10683467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human immunoglobulin G subclass immune response to outer membrane antigens in meningococcal group B vaccine.
    Wedege E; Michaelsen TE
    J Clin Microbiol; 1987 Aug; 25(8):1349-53. PubMed ID: 3114315
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preparation and physicochemical and immunological characterization of polysaccharide-outer membrane protein complexes of Neisseria meningitidis.
    Beuvery EC; Miedema F; van Delft RW; Haverkamp J; Leussink AB; te Pas BJ; Teppema KS; Tiesjema RH
    Infect Immun; 1983 Apr; 40(1):369-80. PubMed ID: 6403470
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunologic priming to capsular polysaccharide in infants immunized with Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine.
    Weinberg GA; Einhorn MS; Lenoir AA; Granoff PD; Granoff DM
    J Pediatr; 1987 Jul; 111(1):22-7. PubMed ID: 3110388
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epitope specificity of murine and human bactericidal antibodies against PorA P1.7,16 induced with experimental meningococcal group B vaccines.
    Rouppe van der Voort EM; Kuipers B; Brugghe HF; van Unen LM; Timmermans HA; Hoogerhout P; Poolman JT
    FEMS Immunol Med Microbiol; 1997 Mar; 17(3):139-48. PubMed ID: 9093834
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of meningococcal epitopes in LamB of Escherichia coli and the stimulation of serosubtype-specific antibody responses.
    McCarvil J; McKenna AJ; Grief C; Hoy CS; Sesardic D; Maiden MC; Feavers IM
    Mol Microbiol; 1993 Oct; 10(1):203-13. PubMed ID: 7526119
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Class-specific human bactericidal antibodies to capsular and noncapsular surface antigens of Neisseria meningitidis.
    Skevakis L; Frasch CE; Zahradnik JM; Dolin R
    J Infect Dis; 1984 Mar; 149(3):387-96. PubMed ID: 6425422
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them.
    Holst J
    Hum Vaccin; 2007; 3(6):290-4. PubMed ID: 17712231
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease.
    Boslego J; Garcia J; Cruz C; Zollinger W; Brandt B; Ruiz S; Martinez M; Arthur J; Underwood P; Silva W
    Vaccine; 1995 Jun; 13(9):821-9. PubMed ID: 7483804
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Construction of a multivalent meningococcal vaccine strain based on the class 1 outer membrane protein.
    Van Der Ley P; Poolman JT
    Infect Immun; 1992 Aug; 60(8):3156-61. PubMed ID: 1639486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.